Skip to content
Peptigraph home

Petrelintide Phase 2 trial (NCT06926842)

A Randomized, Double-Blind, Phase 2 Trial of Once-Weekly Petrelintide Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
221
actual
Start
22 Apr 2025 (actual)
Primary completion
13 Aug 2026 (actual)
Sponsor
Zealand Pharma
Design

Arms and doses

NCT06926842 study arms
ArmTypeInterventionsDescription
Treatment A: Petrelintide Dose 1ExperimentalDrug: PetrelintideRandomized participants will receive weekly subcutaneous injections of petrelintide Dose 1.
Treatment B: Petrelintide Placebo Dose 1Placebo comparatorOther: PlaceboRandomized participants will receive weekly subcutaneous injections of matching placebo to petrelintide.
Treatment C: Petrelintide Dose 2ExperimentalDrug: PetrelintideRandomized participants will receive weekly subcutaneous injections of petrelintide Dose 2.
Treatment D: Petrelintide Placebo Dose 2Placebo comparatorOther: PlaceboRandomized participants will receive weekly subcutaneous injections of matching placebo to petrelintide.
Treatment E: Petrelintide Dose 3ExperimentalDrug: PetrelintideRandomized participants will receive weekly subcutaneous injections of petrelintide Dose 3.
Treatment F: Petrelintide Placebo Dose 3Placebo comparatorOther: PlaceboRandomized participants will receive weekly subcutaneous injections of matching placebo to petrelintide.
Endpoints

Primary endpoint

NCT06926842 primary outcomes
MeasureTime frame
Percentage Change in Body WeightFrom Baseline (Day 1) to Weeks 28
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT06926842 secondary outcomes
MeasureTime frame
Number of Participants Achieving ≥5% Body Weight LossFrom Baseline (Day 1) to Weeks 28
Number of Participants Achieving ≥10% Body Weight LossFrom Baseline (Day 1) to Weeks 28
Change in Body Weight (kilogram)From Baseline (Day 1) to Weeks 28
Change in Waist CircumferenceFrom Baseline (Day 1) to Weeks 28
Change in Glycated Hemoglobin (HbA1c)From Baseline (Day 1) to Weeks 28
Change in Fasting GlucoseFrom Baseline (Day 1) to Weeks 28
Change in High-Sensitivity C-reactive protein (hsCRP)From Baseline (Day 1) to Weeks 28
Number of Participants Achieving ≤6.5% HbA1cFrom Baseline (Day 1) to Weeks 28
Changes in Fasting LipidsFrom Baseline (Day 1) to Weeks 28
Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)From Baseline (Day 1) to Weeks 38
Number of Participants with Treatment- Emergent Severe or Clinically Significant Hypoglycemic Episodes from Baseline to Week 38From Baseline (Day 1) to Weeks 38
Number of Participants with Positive Anti-Drug Antibodies (ADAs)From Baseline (Day 1) to Weeks 38
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1A Randomized, Double-Blind, Phase 2 Trial of Once-Weekly Petrelintide Compared With Placebo in Participants With Overweight or Obesity and Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.